Cargando…

Plasma proteomic profiling in postural orthostatic tachycardia syndrome (POTS) reveals new disease pathways

Postural orthostatic tachycardia syndrome (POTS) is a cardiovascular autonomic disorder characterized by excessive heart rate increase on standing, leading to debilitating symptoms with limited therapeutic possibilities. Proteomics is a large-scale study of proteins that enables a systematic unbiase...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansson, Madeleine, Yan, Hong, Welinder, Charlotte, Végvári, Ákos, Hamrefors, Viktor, Bäck, Magnus, Sutton, Richard, Fedorowski, Artur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681882/
https://www.ncbi.nlm.nih.gov/pubmed/36414707
http://dx.doi.org/10.1038/s41598-022-24729-x
_version_ 1784834725180866560
author Johansson, Madeleine
Yan, Hong
Welinder, Charlotte
Végvári, Ákos
Hamrefors, Viktor
Bäck, Magnus
Sutton, Richard
Fedorowski, Artur
author_facet Johansson, Madeleine
Yan, Hong
Welinder, Charlotte
Végvári, Ákos
Hamrefors, Viktor
Bäck, Magnus
Sutton, Richard
Fedorowski, Artur
author_sort Johansson, Madeleine
collection PubMed
description Postural orthostatic tachycardia syndrome (POTS) is a cardiovascular autonomic disorder characterized by excessive heart rate increase on standing, leading to debilitating symptoms with limited therapeutic possibilities. Proteomics is a large-scale study of proteins that enables a systematic unbiased view on disease and health, allowing stratification of patients based on their protein background. The aim of the present study was to determine plasma protein biomarkers of POTS and to reveal proteomic pathways differentially regulated in POTS. We performed an age- and sex-matched, case–control study in 130 individuals (case–control ratio 1:1) including POTS and healthy controls. Mean age in POTS was 30 ± 9.8 years (84.6% women) versus controls 31 ± 9.8 years (80.0% women). We analyzed plasma proteins using data-independent acquisition (DIA) mass spectrometry. Pathway analysis of significantly differently expressed proteins was executed using a cutoff log2 fold change set to 1.2 and false discovery rate (p-value) of < 0.05. A total of 393 differential plasma proteins were identified. Label-free quantification of DIA-data identified 30 differentially expressed proteins in POTS compared with healthy controls. Pathway analysis identified the strongest network interactions particularly for proteins involved in thrombogenicity and enhanced platelet activity, but also inflammation, cardiac contractility and hypertrophy, and increased adrenergic activity. Our observations generated by the first use a label-free unbiased quantification reveal the proteomic footprint of POTS in terms of a hypercoagulable state, proinflammatory state, enhanced cardiac contractility and hypertrophy, skeletal muscle expression, and adrenergic activity. These findings support the hypothesis that POTS may be an autoimmune, inflammatory and hyperadrenergic disorder.
format Online
Article
Text
id pubmed-9681882
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-96818822022-11-24 Plasma proteomic profiling in postural orthostatic tachycardia syndrome (POTS) reveals new disease pathways Johansson, Madeleine Yan, Hong Welinder, Charlotte Végvári, Ákos Hamrefors, Viktor Bäck, Magnus Sutton, Richard Fedorowski, Artur Sci Rep Article Postural orthostatic tachycardia syndrome (POTS) is a cardiovascular autonomic disorder characterized by excessive heart rate increase on standing, leading to debilitating symptoms with limited therapeutic possibilities. Proteomics is a large-scale study of proteins that enables a systematic unbiased view on disease and health, allowing stratification of patients based on their protein background. The aim of the present study was to determine plasma protein biomarkers of POTS and to reveal proteomic pathways differentially regulated in POTS. We performed an age- and sex-matched, case–control study in 130 individuals (case–control ratio 1:1) including POTS and healthy controls. Mean age in POTS was 30 ± 9.8 years (84.6% women) versus controls 31 ± 9.8 years (80.0% women). We analyzed plasma proteins using data-independent acquisition (DIA) mass spectrometry. Pathway analysis of significantly differently expressed proteins was executed using a cutoff log2 fold change set to 1.2 and false discovery rate (p-value) of < 0.05. A total of 393 differential plasma proteins were identified. Label-free quantification of DIA-data identified 30 differentially expressed proteins in POTS compared with healthy controls. Pathway analysis identified the strongest network interactions particularly for proteins involved in thrombogenicity and enhanced platelet activity, but also inflammation, cardiac contractility and hypertrophy, and increased adrenergic activity. Our observations generated by the first use a label-free unbiased quantification reveal the proteomic footprint of POTS in terms of a hypercoagulable state, proinflammatory state, enhanced cardiac contractility and hypertrophy, skeletal muscle expression, and adrenergic activity. These findings support the hypothesis that POTS may be an autoimmune, inflammatory and hyperadrenergic disorder. Nature Publishing Group UK 2022-11-21 /pmc/articles/PMC9681882/ /pubmed/36414707 http://dx.doi.org/10.1038/s41598-022-24729-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Johansson, Madeleine
Yan, Hong
Welinder, Charlotte
Végvári, Ákos
Hamrefors, Viktor
Bäck, Magnus
Sutton, Richard
Fedorowski, Artur
Plasma proteomic profiling in postural orthostatic tachycardia syndrome (POTS) reveals new disease pathways
title Plasma proteomic profiling in postural orthostatic tachycardia syndrome (POTS) reveals new disease pathways
title_full Plasma proteomic profiling in postural orthostatic tachycardia syndrome (POTS) reveals new disease pathways
title_fullStr Plasma proteomic profiling in postural orthostatic tachycardia syndrome (POTS) reveals new disease pathways
title_full_unstemmed Plasma proteomic profiling in postural orthostatic tachycardia syndrome (POTS) reveals new disease pathways
title_short Plasma proteomic profiling in postural orthostatic tachycardia syndrome (POTS) reveals new disease pathways
title_sort plasma proteomic profiling in postural orthostatic tachycardia syndrome (pots) reveals new disease pathways
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681882/
https://www.ncbi.nlm.nih.gov/pubmed/36414707
http://dx.doi.org/10.1038/s41598-022-24729-x
work_keys_str_mv AT johanssonmadeleine plasmaproteomicprofilinginposturalorthostatictachycardiasyndromepotsrevealsnewdiseasepathways
AT yanhong plasmaproteomicprofilinginposturalorthostatictachycardiasyndromepotsrevealsnewdiseasepathways
AT welindercharlotte plasmaproteomicprofilinginposturalorthostatictachycardiasyndromepotsrevealsnewdiseasepathways
AT vegvariakos plasmaproteomicprofilinginposturalorthostatictachycardiasyndromepotsrevealsnewdiseasepathways
AT hamreforsviktor plasmaproteomicprofilinginposturalorthostatictachycardiasyndromepotsrevealsnewdiseasepathways
AT backmagnus plasmaproteomicprofilinginposturalorthostatictachycardiasyndromepotsrevealsnewdiseasepathways
AT suttonrichard plasmaproteomicprofilinginposturalorthostatictachycardiasyndromepotsrevealsnewdiseasepathways
AT fedorowskiartur plasmaproteomicprofilinginposturalorthostatictachycardiasyndromepotsrevealsnewdiseasepathways